ABOUT ISNR

Directors | Staff | Committee Chair Persons |NeuroRegulation Journal
Standards Policies | Disclaimers

DIRECTORS

Rob Coben

President
Rob Coben, PhD
Contact him

Rex CannonPast President
Rex Cannon, PhD
Contact him

Nancy WigtonTreasurer
Nancy Wigton, PhD
Contact her

Joseph BarrSecretary
Joseph Barr, PhD
Contact him

Dan WilliamsSergeant at Arms
Dan Williams, PT
Contact him

Kirk LittlePresident Elect
Kirk Little, PsyD
Contact him

Amber FasulaMember at Large
Amber Fasula, PsyD
Contact her

Rob LongoMember at Large
Robert Longo, MRC
Contact him

Pedro DelgadoInternational
Member at Large
Pedro Delgado, MD
Contact him

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

STAFF

Executive DirectorCindy Yablonski
Cindy A. Yablonski, MBA
Contact Her

   

 

 

 

 

 

COMMITTEE CHAIRPERSONS

Executive Committee, Rob Coben, PhD
Board Advisory, Rob Coben, PhD
Conference, Dan Williams, PT
Education, Rob Coben, PhD
Ethics, Hank Weeks, PhD
Finance, Nancy Wigton, MA
Membership, Rob Coben, PhD
Newsletter, Merlyn Hurd, PhD
Student Advocacy, Sarah Wyckoff, PhD
Nominations, Rob Coben, PhD
Personnel, Rex Cannon, PhD
Public Relations and Outreach, Kirk Little, PsyD.
Structure, Rex Cannon, PhD
Committee on QEEG Certification Nancy White, PhD
Website Committee, Joseph Barr, PhD

NeuroRegulation Journal: Investigations in Neuromodulation, Neurofeedback and Applied Neuroscience

Senior Editor, NeuroRegulation Journal, Adam Clarke, PhD

NeuroRegulation Journal PAGE

  


STANDARDS POLICY FOR SUBMISSION TO THE CONFERENCE (exhibiting and presenting) AND JOURNAL (articles)

Methods of application are:

1) submission for publication in the NeuroRegulation Journal,
2) submission for presentation at the annual ISNR conference or
3) application for exhibiting as a vendor at the annual ISNR conference 

 

ISNR Board of Directors, NeuroRegulation Journal editorial staff and the ISNR Annual Conference Committee encourage individuals and companies to submit scholarly articles, professional presentations related to the field of Neurofeedback, Neuromodulation and Applied Neuroscience and products of interest to the members of the Society. The following are guidelines intended to assist in the application process for submissions of any of the aforementioned 3 types. In order to facilitate the progress of the field and to keep the conference, Journal and vendor’s hall as relevant and current as possible presentations, research articles and specific applications of therapeutic application should seek to demonstrate how the material, results, or intervention has advanced from the initial presentation.

If the same topic has been presented in the previous two years then the review committee will consider if the application, protocol or intervention has extended the original research beyond the first presentation. Considering the challenges of conducting research in clinical settings, the committee encourages multiple options for valid research and statistical evaluation methods of the primary and secondary submissions only.  These include feasibility studies where a smaller number of clients may be used to evaluate the use of neuromodulation techniques in novel settings and/or with novel populations; evaluation of response rate rather than symptom reduction; allocation studies (for example using biomarkers, or endophenotypes, to assign clients to treatments that may best help their symptom); and risk development studies.  It is strongly encouraged that repeated presentations/applications should have enacted a research program which has achieved “Level 3: Probably Effective” of the ISNR/AAPB guidelines for rating clinical effectiveness (see below).

Examples of the application of these guidelines for tertiary and subsequent submissions are: A submission to the Journal for the treatment of ADHD would have to present research that will move beyond or add to the established level of efficacy for the treatment of ADHD (Level 5 per ISNR Position Paper JNT 14/3); A presentation or workshop on z-score treatment of some condition that has been presented for two years running would need to demonstrate that it had engaged in a research program that moved the evidence of efficacy beyond that presented in the previous two presentations; A vendor promoting a specific treatment modality or form of intervention which had garnered a level 1 or 2 Level of efficacy at its initial and following demonstrations would be able to demonstrate additional research that the protocol, intervention or method of application had advanced beyond the initial levels. The methods of research used to demonstrate levels of efficacy should be appropriate to the phenomena under investigation. Peer reviewers involved in the Journal of Neurotherapy, the conference committee and the Board of Directors will be responsible for evaluating and determining whether submissions have fulfilled the appropriate criteria.

Level 1:            Supported only by anecdotal reports and/or case studies in non-peer reviewed venues. Not empirically supported.
Level 2:            Possibly Efficacious. At least one study of sufficient statistical power with well identified outcome measures, but lacking randomized assignment to a control condition internal to the study
Level 3:            Probably Efficacious. Multiple observational studies, clinical studies, wait list controlled studies, and within-subject and intrasubject replication studies that demonstrate efficacy.
Level 4:            Efficacious: (a) In a comparison with a no-treatment control group, alternative treatment group, or sham (placebo) control utilizing randomized assignment, the investigational treatment is shown to be statistically significantly superior to the control condition or the investigational treatment is equivalent to a treatment of established efficacy in a study with sufficient power to detect moderate differences, (b) The studies have been conducted with a population treated for a specific problem, for whom inclusion criteria are delineated in a reliable, operationally defined manner, (c) The study used valid and clearly specified outcome measures related to the problem being treated, (d) The data are subjected to appropriate data analysis, (e) The diagnostic and treatment variables and procedures are clearly defined in a manner that permits replication of the study by independent researchers, and (f) The superiority or equivalence of the investigational treatment has been shown in at least two independent research settings.

Level 5: Efficacious and Specific. The investigational treatment has been shown to be statistically superior to credible sham therapy, pill, or alternative bona fide treatment in at least two independent research settings or has empirically demonstrated equivalent or superior symptom alleviation on accepted outcome measures as compared to the current accepted standard of care.

About ISNR

The International Society for Neurofeedback & Research (ISNR) is a membership organization comprised of people from many countries and various professional disciplines doing neurotherapy, neurofeedback training and research. ISNR supports education and excellence in the field of neurofeedback training and neurotherapy and seeks the validation and acceptance of this discipline by a broad spectrum of society.

Both the society and its members gladly cooperate with other like-minded organizations and individuals. Today, neurofeedback, also called EEG biofeedback or EEG operant conditioning, is the most commonly used form of neuronal regulation. It is often used in conjunction with other forms of biofeedback as well as with whatever other professional services its practitioners are additionally qualified and licensed to render such as, psychology, medicine, clinical social work, nursing, education, counseling, etc. Persons who fit within this framework are cordially invited to submit an application for membership.

Quantitative EEG (QEEG) or brain mapping is commonly used to guide the most efficient application of neurofeedback.

The original name of the society from 1995 through 1998 was, Society for the Study of Neuronal Regulation, but it was shortened to Society for Neuronal Regulation for simplicity and to better convey the purposes of the organization. The name was changed again in 2002 to International Society for Neuronal Regulation and again in 2006 to International Society for Neurofeedback & Research to better reflect the fact that members of the society now came from all parts of the globe, not just North America and that research is a critical function of the society.

ISNR members, prospective members, and the public are invited to review the. . . Articles of Incorporation and ISNR Bylaws.

DISCLAIMERS

  1. The International Society for Neurofeedback & Research (ISNR) is providing all contents and materials within its own web site as a public informational service only.
  2. ISNR makes absolutely no endorsement of any statement made in any of the internal materials provided within this site nor of any statement made in any materials obtained from external links listed at this site.
  3. The Board of Directors of ISNR wishes to clarify that ISNR has no association whatsoever with any EEG biofeedback or neurofeedback certifying organization. ISNR is a membership organization which draws its members from fields of medicine, psychology, psychophysiology, counseling, social work, nursing, education and other related fields.

International Society for Neurofeedback & Research

Executive Director, PMB 114, 1350 Beverly Road, Suite 115, McLean, VA 22101-3633 - (703) 848-1994 - Fax (703) 738-7341